Raymond James & Associates cut its stake in shares of Intersect ENT (NASDAQ:XENT) by 3.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 90,274 shares of the medical equipment provider’s stock after selling 2,747 shares during the period. Raymond James & Associates’ holdings in Intersect ENT were worth $2,925,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of the business. Teachers Retirement System of The State of Kentucky raised its position in Intersect ENT by 4.1% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 42,584 shares of the medical equipment provider’s stock worth $1,380,000 after acquiring an additional 1,696 shares during the period. Two Sigma Investments LP raised its position in Intersect ENT by 41.7% during the fourth quarter. Two Sigma Investments LP now owns 144,500 shares of the medical equipment provider’s stock worth $4,682,000 after acquiring an additional 42,558 shares during the period. Two Sigma Advisers LP raised its position in Intersect ENT by 222.3% during the fourth quarter. Two Sigma Advisers LP now owns 36,100 shares of the medical equipment provider’s stock worth $1,170,000 after acquiring an additional 24,900 shares during the period. Stone Ridge Asset Management LLC acquired a new position in Intersect ENT during the fourth quarter worth $300,000. Finally, Thrivent Financial For Lutherans raised its position in Intersect ENT by 8.8% during the fourth quarter. Thrivent Financial For Lutherans now owns 256,053 shares of the medical equipment provider’s stock worth $8,296,000 after acquiring an additional 20,770 shares during the period. Institutional investors own 84.49% of the company’s stock.
Intersect ENT stock opened at $36.60 on Friday. Intersect ENT has a 52-week low of $15.90 and a 52-week high of $40.00. The firm has a market cap of $1,116.19, a PE ratio of -65.36 and a beta of 0.75.
Intersect ENT (NASDAQ:XENT) last released its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.06. Intersect ENT had a negative net margin of 16.99% and a negative return on equity of 14.40%. The business had revenue of $29.53 million during the quarter, compared to analyst estimates of $29.45 million. equities research analysts forecast that Intersect ENT will post -0.61 EPS for the current fiscal year.
In related news, CFO Jeryl L. Hilleman sold 12,833 shares of the company’s stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $37.66, for a total value of $483,290.78. Following the completion of the sale, the chief financial officer now owns 36,265 shares of the company’s stock, valued at $1,365,739.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Richard E. Kaufman sold 50,000 shares of the company’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $33.33, for a total transaction of $1,666,500.00. Following the completion of the sale, the chief operating officer now directly owns 107,470 shares of the company’s stock, valued at approximately $3,581,975.10. The disclosure for this sale can be found here. Insiders have sold 153,458 shares of company stock valued at $5,377,798 in the last ninety days. Insiders own 13.70% of the company’s stock.
A number of equities analysts have weighed in on the stock. Zacks Investment Research restated a “hold” rating on shares of Intersect ENT in a research report on Saturday. BidaskClub raised shares of Intersect ENT from a “hold” rating to a “buy” rating in a report on Monday, February 5th. ValuEngine raised shares of Intersect ENT from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $36.00 target price on shares of Intersect ENT in a report on Monday, December 11th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $33.38.
TRADEMARK VIOLATION NOTICE: “Raymond James & Associates Has $2.93 Million Position in Intersect ENT (XENT)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/raymond-james-associates-has-2-93-million-position-in-intersect-ent-xent.html.
Intersect ENT Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT (NASDAQ:XENT).
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.